Biofrontera (NASDAQ:BFRIW – Get Free Report) will likely be issuing its results after the market closes on Friday, August 7th. Analysts expect the company to announce earnings of ($0.1050) per share and revenue of $9.50 million for the quarter.
Biofrontera Price Performance
Shares of NASDAQ:BFRIW opened at $0.03 on Thursday. The firm has a fifty day moving average of $0.03 and a two-hundred day moving average of $0.04. Biofrontera has a 12-month low of $0.02 and a 12-month high of $0.19.
Biofrontera Company Profile
Biofrontera AG is a biopharmaceutical company headquartered in Leverkusen, Germany, specializing in the development, manufacture and commercialization of dermatology products. Founded in 1997, the company focuses on therapies for skin diseases through innovative drug and device combinations. Its core business centers on photodynamic therapy, where a photosensitizing agent is activated by a specialized light source to treat precancerous and cancerous skin conditions.
The company’s flagship product, Ameluz, is a topical formulation of aminolevulinic acid used in conjunction with the BF-RhodoLED irradiation device.
Read More
- Five stocks we like better than Biofrontera
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.jpg){kind=logo}